Navigation Links
PuraMed BioScience, Inc. Has Its Lead Product, LipiGesic®M Featured in Flaherty Financial News

SCHOFIELD, Wis., Dec. 28, 2011 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB: PMBS) is pleased to announce that its lead product, LipiGesic®M, for the acute treatment of migraines, has been featured in the December 20, 2011 issue of Flaherty Financial News Newsletter published by Flaherty  Financial News Inc.  The report can be found at  

"We are very excited to be featured in the Flaherty Financial News Newsletter," said PuraMed CEO, Russ Mitchell.  "This publication has online distribution to over 10 million investors and we think this is a great step in getting the word out about our product, LipiGesic®M." 

About Flaherty Financial News Inc.
Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of the neglected micro-and small-cap markets. It was launched in February 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., together with his son Brian, who serves as President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years until it was sold in September 2006, Bob was also Editor-in-Chief of Equities Special Situations, which had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. Previously, he was an award-winning Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School.

About the PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products.  PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study.  LipiGesic®M has national distribution and is available nationwide in some of the largest chain drug stores in the United States.  In addition to LipiGesic®M, the Company also has plans to launch LipiGesic®H for tension-type headaches as well as LipiGesic®PM which provides a remedy for insomnia and other sleep disorders.

Forward-Looking Statements:  
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO

Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy

SOURCE PuraMed BioScience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Crown Bioscience, Inc. Announces Closing of Series C Financing
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
3. FDA Tentatively Approves Intellijects Lead Product, e-cue™
4. PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184
5. Equinox Surgical Solutions Launches Flagship Product, SutureAssist®
6. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
7. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
8. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
9. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
10. Nonin Medical GO2™ Finger Pulse Oximeter to be Featured on "The Balancing Act" TV Show on Lifetime Television
11. ClinStar to Be Featured on Business Day TV With Terry Bradshaw
Post Your Comments:
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
Breaking Medicine Technology:
(Date:11/25/2015)... Omaha, Neb. (PRWEB) , ... November 25, 2015 ... ... nurse staffing companies, has been recognized once again for its stellar workplace culture ... Places to Work.” , Medical Solutions’ Cincinnati office was named a ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... and athletic programs, launches new Wimbledon Athletics Facebook page to educate ... athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 ...
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment ... struggling with eating disorders as a result of the $20,000 raised at the ... at Fox Run Golf Club in Eureka, will help individuals who otherwise might ...
Breaking Medicine News(10 mins):